PI Industries Q4 Review - Next Growth Phase To Emanate From Pharma Venture: ICICI Direct
A technician conducts a test on a sample inside the laboratory (Photographer: Sanjit Das/Bloomberg)

PI Industries Q4 Review - Next Growth Phase To Emanate From Pharma Venture: ICICI Direct


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

PI Industries Ltd. reported topline growth of 40% YoY to Rs 1,197 crore against our estimate of Rs 1,185 crore.

Growth was led by the custom synthesis manufacturing business, up 47% YoY to Rs 1,006 crore.

Revenue from domestic agri input was up 11% YoY to Rs 191 crore, largely driven by Isagro (up 52% YoY).

Revenue from domestic branded formulation fell 11% YoY to Rs 100 crore.

Change in the product mix and removal of Merchandise Exports From India Scheme benefits affected gross margins, which was down 469 basis points YoY to 42.1%, translating into a below expected operational performance for the quarter.

Click on the attachment to read the full report:

ICICI Direct PI Industries Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.